{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:11:25Z","timestamp":1790867485884,"version":"4.1.0"},"reference-count":42,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Respirology"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Objective<\/jats:title>\n                    <jats:p>Type 2 (T2) innate lymphoid cells (ILC2s) contribute to airway inflammation and disease in asthma. We hypothesize that ILC2s isolated from people with severe allergic and eosinophilic asthma would exhibit an enhanced T2 inflammatory activity that would be altered following treatment with mepolizumab and omalizumab. We compare peripheral blood (PB) isolated ILC2's proliferative capacity, IL\u20105 and IL\u201013 secretion and phenotype between healthy without asthma (HC), non\u2010asthma allergic (NAA), mild asthma (MA) and severe allergic and eosinophilic asthma (SA) subjects. We then determined the impact of 6\u2009months treatment with either mepolizumab or omalizumab on ILC2s physiology of SA subjects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>ILC2s were sorted and cultured in the presence of IL\u20102, IL\u201025, IL\u201033 and thymic stromal lymphopoietin (TSLP) for 14\u2009days. ILC2s proliferation, phenotypes and functions were assessed using flowcytometry. The ILC2s response was then reassessed following clinically successful treatment of SA subjects with mepolizumab and omalizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>SA ILC2s demonstrated increased proliferative capacity, TSLP receptor (TSLPR), GATA3 and NFATc1 protein expressions and increased IL\u20105 and IL\u201013 release. ILC2s were also capable of releasing IL\u20106 in response to stimulation. Mepolizumab treatment reduced ILC2s proliferative capacity and expression of TSLPR, GATA3 and NFATc1. Both mepolizumab and omalizumab were associated with reduced ILC2s release of IL\u20105 and IL\u201013, only mepolizumab reduced IL\u20106.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ILC2s from severe allergic and eosinophilic asthma demonstrated an active phenotype typified by increased proliferation, TSLPR, GATA3 and NFATc1 expression and increased IL\u20105, IL\u201013 and IL\u20106 release. Mepolizumab reduced markers of ILC2s activation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/resp.14506","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T08:59:17Z","timestamp":1682672357000},"page":"758-766","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Severe asthma\n                    <scp>ILC2s<\/scp>\n                    demonstrate enhanced proliferation that is modified by biologics"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9543-7875","authenticated-orcid":false,"given":"Bilal","family":"Malik","sequence":"first","affiliation":[{"name":"Immune Health Program, Hunter Medical Research Institute University of Newcastle  Callaghan New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan W.","family":"Bartlett","sequence":"additional","affiliation":[{"name":"Immune Health Program, Hunter Medical Research Institute University of Newcastle  Callaghan New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Upham","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Princess Alexandra Hospital  Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristy S.","family":"Nichol","sequence":"additional","affiliation":[{"name":"Immune Health Program, Hunter Medical Research Institute University of Newcastle  Callaghan New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1542-6250","authenticated-orcid":false,"given":"John","family":"Harrington","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Sleep Medicine John Hunter Hospital  New Lambton Heights New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5676-6126","authenticated-orcid":false,"given":"Peter A. B.","family":"Wark","sequence":"additional","affiliation":[{"name":"Immune Health Program, Hunter Medical Research Institute University of Newcastle  Callaghan New South Wales Australia"},{"name":"Department of Respiratory and Sleep Medicine John Hunter Hospital  New Lambton Heights New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,4,28]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2018.1505352"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2018.03.004"},{"key":"e_1_2_10_4_1","article-title":"Omalizumab for asthma in adults and children","volume":"1","author":"Normansell R","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00202013"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2004.00772.x"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808991"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805435"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.11.037"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.05.037"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)62559-X"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2737"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201512-2452OC"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201612-2427OC"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.06.024"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.03.032"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3675"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abd3489"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8607657"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.4137\/CCRPM.S7793"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13815-w"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201948161"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.637948"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000090"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri3739"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.12.8183"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(01)00162-5"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016002352"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206940"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-51690-z"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2623"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2012.06.020"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.01.027"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20170449"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.12.885"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20161274"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.10.056"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.12087"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1101806"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2018.04.043"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201909-1813OC"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abe5084"}],"container-title":["Respirology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/resp.14506","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T07:32:05Z","timestamp":1692257525000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/resp.14506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,28]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1111\/resp.14506"],"URL":"https:\/\/doi.org\/10.1111\/resp.14506","archive":["Portico"],"relation":{},"ISSN":["1323-7799","1440-1843"],"issn-type":[{"value":"1323-7799","type":"print"},{"value":"1440-1843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,28]]},"assertion":[{"value":"2022-09-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}